Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
One Percent Rule Checklist For Safer Forex Trading Risk 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Merck & Co Inc is buying Pandion Therapeutics, the biotechnology company developing bispecific antibody therapeutics headquartered in Massachusetts. It was said that the pharmaceutical firm is shelling out a total of $1.85 billion in cash to acquire it.
Merck’s target expansion
The acquisition was revealed on Feb. 25 through a joint statement from Merck and Pandion Therapeutics. The deal is also equivalent to a $60 per share deal that amounts to a 134% premium to Pandion’s closing price on Wednesday.
As per Fox Business, Merck & Co Inc. is purchasing the said drug developer to broaden its portfolio of drugs designed for autoimmune diseases. With the deal, the pharmaceutical company that is one of the largest in the world is also set to have Pandion’s major drug candidate called PT101, which is currently undergoing testing for public release.
The drug already completed and passed the phase 1a clinical trial last month for safety and tolerability. It is now in the early stage of the trial involving volunteer patients with autoimmune diseases.
“This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational characteristics,” Dr. Dean Y. Li, Merck Research Laboratories president said in a press release. “Pandion has applied its TALON technology to develop a robust pipeline of candidates designed to re-balance the immune response with potential applications across a wide array of autoimmune diseases.”
Merck and Pandion are expected to close the deal before the second half of this year begins. Both companies confirmed this during the announcement this week.
Merck and Pandion’s stocks up after the buyout reveal
The New Jersey-headquartered pharma company is paying more than double Pandion’s current stock price, and the news of this deal drove both Merck and Pandion’s share to shoot up.
Shares of the drug developer closed at $25.63 after the confirmation of the acquisition, while Merck shares increased by 0.3% in premarket trading.
Meanwhile, this was Merck’s latest purchase as it had entered into a number of deals before 2020 closed. One of its major acquisitions was the biotech company VelosBio which was bought for $2.75 billion. It also acquired Oncolmmune, another private firm, for $425 million.
